• CDC News
  • Adult Immunization
  • Hepatology
  • Rare Disorders
  • Pediatric Immunization
  • Weight Management
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Kidney Disease
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Orthopedics
  • Obesity Medicine
  • Rheumatology
  • Technology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Antiobesity Medications: Expert Discusses Older, Newer Therapies

News
Video

Obesity specialist Sandra Christensen, MSN, ARNP, details the differences between older antiobesity medications and newer GLP-1RAs liraglutide and semaglutide 2.4 mg.

How do older antiobesity medications, such as bupropion/naltrexone, phentermine/topirimate, and orlistat differ from the more recently approved GLP-1RAs liraglutide and semaglutide 2.4 mg?

Was a question Patient Care Online asked medical weight management specialist Sandra Christensen, MSN, ARNP, in a recent interview on antiobesity medications.

In the video below, Ms Christensen gives a primer on common antiobesity medications and discusses the differences between older antiobesity medications and newer GLP-1RA therapies.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Overweight and Obesity: One Expert's 3 Wishes for the Future of Patient Care
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
"Obesity is a Medically Approachable Problem" and Other Lessons with Lee Kaplan, MD, PhD
Related Content
Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial / image credit ©Starmarpro/stock.adobe.com

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

Grace Halsey
January 17th 2025
Article

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications

FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications

Grace Halsey
January 8th 2025
Article

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial / image credit ©JHVE photo/stock.adobe.com

CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial, Short of the 25% Expected

Grace Halsey
December 20th 2024
Article

The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.

Investigational Maridebart Cafraglutide Shows Promise for Obesity, T2D: Daily Dose / image credit: ©New Africa/AdobeStock

Investigational Maridebart Cafraglutide Shows Promise for Obesity, T2D: Daily Dose

Sydney Jennings
December 17th 2024
Article

Your daily dose of the clinical news you may have missed.

© 2025 MJH Life Sciences

All rights reserved.